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Abstract
Cesarean birth rates are rising. Uterine dysfunction, the exact mechanism of which is unknown, is a common indication for
Cesarean delivery. Biglycan and decorin are two small leucine-rich proteoglycans expressed in the extracellular matrix of
reproductive tissues and muscle. Mice deficient in biglycan display a mild muscular dystrophy, and, along with mice
deficient in decorin, are models of Ehlers-Danlos Syndrome, a connective tissue anomaly associated with uterine rupture. As
a variant of Ehlers-Danlos Syndrome is caused by a genetic mutation resulting in abnormal biglycan and decorin secretion,
we hypothesized that biglycan and decorin play a role in uterine function. Thus, we assessed wild-type, biglycan, decorin
and double knockout pregnancies for timing of birth and uterine function. Uteri were harvested at embryonic days 12, 15
and 18. Nonpregnant uterine samples of the same genotypes were assessed for tissue failure rate and spontaneous and
oxytocin-induced contractility. We discovered that biglycan/decorin mixed double-knockout dams displayed dystocia, were
at increased risk of delayed labor onset, and showed increased tissue failure in a predominantly decorin-dependent manner.
In vitro spontaneous uterine contractile amplitude and oxytocin-induced contractile force were decreased in all biglycan
and decorin knockout genotypes compared to wild-type. Notably, we found no significant compensation between biglycan
and decorin using quantitative real time PCR or immunohistochemistry. We conclude that the biglycan/decorin mixed
double knockout mouse is a model of dystocia and delayed labor onset. Moreover, decorin is necessary for uterine function
in a dose-dependent manner, while biglycan exhibits partial compensatory mechanisms in vivo. Thus, this model is poised
for use as a model for testing novel targets for preventive or therapeutic manipulation of uterine dysfunction.
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Introduction
The rate of birth by Cesarean section has been rising steadily in
the United States despite the Healthy People 2020 goal of
decreasing Cesarean births. It has increased by 60% since 1996 to
a rate of 32% of all births in 2009 [1]. Common indications
include previous Cesarean birth, breech positioning, fetal distress
and multiple gestation, as well as various clinical scenarios such as
failed induction and failure to progress, which are indicators of
uterine dysfunction [2].
In the physiologic setting, the uterus is dormant during
gestation to avoid preterm birth, then transitions to active
contractions when expulsion of the fetus is necessary. These
processes are modulated by neuronal, hormonal, metabolic and
mechanical factors [3]. A variety of mechanisms have been
implicated in the pathogenesis of uterine dysfunction, or
dystocia. These include increasing maternal age [4], stress and
obesity [5]. In mouse models, genetic mutations may lead to
dystocia. Mice with mutations of Atp11c have dystocia [6], while
overexpression of small conductance calcium-activated K
channel isoform 3 leads to inefficient uterine contractility [7].
Mice with mutations of steroid 5a-reductase, relaxin, cytosolic
phospholipase A2 and the prostaglandin F2 a receptor FP display
dystocia and/or delayed labor onset (reviewed in [8]). However,
the precise mechanism of uterine dysfunction, which is most
likely multifactorial, is unclear.
Biglycan is a small leucine-rich proteoglycans (SLRP) that is a
component of the extracellular matrix in a variety of tissues
including skin, bone, and skeletal as well as cardiac muscle
[9,10,11]. Its core protein contains two chondroitin or dermatan
sulfate side chains [12]. Biglycan binds to collagen VI, transform-
ing growth factor-a (TGF-a), TGF-b, chordin and BMP-4
[13,14,15,16,17,18]. Decorin is a small leucine-rich proteoglycan
with one chondroitin or dermatan sulfate side chain that
demonstrates ,55% homology with biglycan [19] and also
interacts with a number of extracellular matrix constituents and
growth factors [20,21].
Biglycan and decorin are expressed in a variety of gestational
tissues in humans, including the placenta [22] and fetal
membranes [23,24,25,26]. Biglycan is expressed in the pregnant
mouse uterus [27,28], while both biglycan and decorin are
decreased in the human myometrium during labor [29].
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Ehlers-Danlos syndrome (EDS), a heterogeneous group of rare
inherited connective tissue disorders associated with aneurysms as
well as uterine rupture and a decrease in tensile strength and
integrity of skin, joints, and other connective tissues. These mice
display connective tissue anomalies of skin, bone and tendon [30].
In patients afflicted with the progeroid variant of EDS, the
molecular basis of the connective tissue anomaly is a mutation
of xylosylprotein-4ß-galactosyltransferase I, an enzyme that is
necessary for the posttranslational modification leading to the
glycosylation of biglycan and decorin. This mutation leads to the
abnormal secretion of biglycan and decorin core protein lacking
glycosaminoglycan side chains [31,32].
Women with EDS type IV are at increased risk of uterine
rupture [33,34] and atonic uterus at Cesarean section [35], while
infants born with type III Ehlers-Danlos syndrome may be at
increased risk of malpresentation during labor [36].
We previously reported that biglycan is developmentally
regulated in mouse skeletal muscle as well as in skeletal and
diaphragm muscle in human fetuses [37]. Furthermore, the
biglycan knockout mouse displays mild muscular dystrophy [38].
In the decorin knockout mouse, the decidualized stroma of the
uterus shows abnormal architecture with large diameters and
irregular contours of the endometrial collagen fibrils [39].
Furthermore, we have shown that the biglycan/decorin double
knockout mouse displays preterm birth [40]. However, little is
known about the role that these proteoglycans play in the function
of uterine muscle. Thus, we hypothesized that biglycan and
decorin could be protective of uterine smooth muscle dysfunction
and that the absence of biglycan and decorin would lead to labor
dystocia and adverse gestational outcomes. Our findings demon-
strate for the first time that the absence of these two key SLRPs
favors dystocia. Thus, this double knockout mouse could represent
a novel and invaluable tool for testing new therapeutic approaches
for the treatment and prevention of human dystocia.
Materials and Methods
Ethics Statement
Women and Infants’ Hospital Institutional Animal Care and
Use Committee approval was obtained and steps were taken to
minimize the suffering of animals (Approval # 0077-09).
Mouse Husbandry
C3H wild-type mice were purchased from Jackson Laboratories
(Bar Harbor, ME). A homozygous biglycan knockout (Bgn2/2
Dcn+/+) breeding pair of C3H background (generated by Marian
Young [41]) was a gift from Justin Fallon. A heterozygous decorin
knockout (Bgn+/+Dcn+/2) breeding pair of C57BL background
was mated to the birth of homozygous pups (Bgn+/+Dcn2/2),
which were then bred to establish the homozygous decorin
knockout colony. Mice were housed under standard conditions. A
homozygous biglycan knockout female was crossed with a
homozygous decorin knockout male to establish breeding pairs
in which the females were heterozygous for both biglycan and
decorin (Bgn+/2Dcn+/2) and the males were heterozygous for
decorin but homozygous knockouts for biglycan (Bgn2/
0Dcn+/2),
given that biglycan is an X-chromosomal gene. These pairs were
mated to breed mixed genotype litters to gain Bgn2/2Dcn+/2,
Bgn+/2Dcn2/2 and Bgn2/2Dcn2/2 females as well as Bgn2/2
Dcn+/+ females of mixed C3H/C57BL background. Wild-type
females, Bgn2/2Dcn+/+ females and Bgn+/+Dcn2/2 females
were bred with males of their own genotype. Bgn+/2Dcn+/2,
Bgn+/2Dcn2/2, Bgn2/2Dcn+/2 and Bgn2/2Dcn2/2 females
were bred with Bgn2/
0Dcn+/2 males given our observation that
Bgn2/
0 Dcn2/2 males do not produce pregnancies. Breeding
pairs were set up in the evening. Plugs were checked the
following morning and every morning thereafter. The day ofthe
plug was defined as embryonic day 0. Cages were observed each
morning for litters as well as parturition activity. The morning
that a litter was observed was defined as the day of birth (P0).
Pairs were set up for mating at 5–7 weeks. A subgroup of
pregnant dams was sacrificed at E12, E15 and E18. Data was
collected on length of pregnancy and presence or absence of
dystocia.
Genotyping
A 3-mm tail biopsy specimen was obtained for each pup within
a mixed genotype litter at weaning (around postnatal day 21).
Genomic DNA was extracted from each tail biopsy sample using
the High Pure PCR Template Preparation Kit (Roche, Mann-
heim, Germany). Polymerase chain reaction (PCR) was performed
to identify the decorin and biglycan alleles using the Taq DNA
Polymerase kit (New England Biolabs, Ipswich, MA) and the PTC-
200 thermal cycler. The PCR product was run on a 1.8% w/v
agarose gel to visualize the following diagnostic bands. The
decorin PCR produced bands of 161 bp for the wild-type allele
and 238 bp for the knockout allele. The biglycan PCR produced
bands of 212 bp and 310 bp for the wild-type and knockout
alleles, respectively.
Tissue Failure Rate to Standard Load and Contraction
8–13 week old virgin female mice of the following genotypes
and background strains were used: wild-type (Bgn+/+Dcn+/+ C3H),
Bgn2/2Dcn+/+ C3H, Bgn+/+Dcn2/2 C57BL and Bgn2/2
Dcn2/2 C3H/C57BL. In order to elucidate a possible contribu-
tion of the background to the observed phenotype, a crossed
background Bgn2/2Dcn+/+ (C3H/C57BL) was also generat-
ed. After sacrifice, the uteri were exposed by laparotomy and
dissected from the abdominal cavity with care taken to avoid
stretching the tissue. The tissue was placed in cold (4uC)
physiological salt solution (PSS) containing (in mM): 140 NaCl,
4.7 KCl, 1.2 Na2HPO4, 2.0 MOPS (pH 7.4), 0.02 Na2EDTA,
1.2 MgSO4, 1.6 CaCl2, and 5.6 D-glucose. Connective tissue
and the cervix were removed under a dissection microscope
using microdissecting scissors to expose an individual segment
from each uterine horn.
Two stainless steel wire clamps were used to hold each uterine
horn segment in place. One wire clamp was connected to a force
transducer (Grass FT 03, Grass Technologies, West Warwick, RI)
while the other was secured by a glass rod mounted on a length
manipulator (Narishige, Tokyo, Japan). The force transducers
were connected to a laptop via a Model 7E Poly Graph amplifier
with a Polyview Adapter Unit (PVA-16, Grass Technologies, West
Warwick, RI). For the studies of tissue failure rate to standard load,
the uterine segments were exposed to a standard of 10 g of force.
Tissue failure (tearing) or lack thereof was recorded. For the
contraction force studies, the same experimental setup was used.
After exposure to 10 g of loading force, the tissue was allowed to
equilibrate for 1 h in PSS at 37uC and bubbled with air (21%
oxygen, 79% nitrogen) to avoid hypoxia. After equilibration, the
segments were activated for 3 min by K-PSS (similar in
composition to PSS except that 104.95 mM NaCl was substituted
for by an equimolar concentration of KCl) [42]. After activation,
the tissue was relaxed in PSS for one hour (baseline); then, the
uterine segments were exposed to increasing dosages of oxytocin at
concentrations of 0.01 nM, 1 nM and 100 nM for 15 min each.
Dystocia in Biglycan/Decorin Knockout Mice
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30 min in PSS.
Data Analysis
For the contraction studies, contraction activity was recorded in
Polyview Recorder (Grass Technologies, West Warwick, RI).
Using Polyview Reviewer (Grass Technologies, West Warwick,
RI), the average amplitude of the wave forms was measured in
PSS over a 40 minute period (starting at 10 min after the start of
the recording). Also, the mean integral of the contraction tracings
was calculated over the following intervals: One hour equilibra-
tion: 10 min after start to 10 min before K-PSS added. K-PSS:
From addition of K-PSS to beginning of relaxation in PSS
(baseline). One hour relaxation: 10 min after start to 10 min
before addition of 0.01 nM oxytocin. 15 min oxytocin trials:
5 min after start to beginning of next trial. Recovery: 10 min after
start to end of recording. Each mean integral was normalized to
the trial’s mean integral during the one hour equilibration. In cases
in which two uterine segments from one mouse were used, their
mean integrals were averaged before normalization. Results for
Bgn2/2Dcn+/+ females of both C3H and C3H/C57BL back-
ground strains were compared.
RNA/cDNA Preparation and Quantitative PCR
Wild-type, Bgn2/2Dcn+/+ and Bgn+/+Dcn2/2 uterus was
dissected at three prenatal time points (E12, E15 and E18) in
0.1 M PBS, pH 7.4, snap-frozen in liquid nitrogen and stored at
280uC. RNA extraction was performed using the Trizol method
(Invitrogen, Carlsbad, CA, Carlsbad, CA). Genomic DNA was
removed by incubating the RNA sample with DNase I (Invitrogen,
Carlsbad, CA) for 30 min at 37uC with subsequent RNA re-
extraction with Trizol. The purified RNA was converted to cDNA
using the Superscript III First-Strand Synthesis System Kit
(Invitrogen, Carlsbad, CA). qPCR reactions were performed on
the ABI PRISM 7000 real-time thermocycler (Applied Biosystems,
Foster City, CA) and on the Eppendorf Mastercycler epgradient S
(Eppendorf, Hamburg, Germany) using the SYBR-Green method
(Invitrogen, Carlsbad, CA). Primers were designed using Primer-
Blast primer design software (National Library of Medicine,
Bethesda, MD). The values were normalized to the housekeeping
gene Gapdh. Melting point analysis of the product was performed
to ensure the absence of alternative products or primer dimers.
Data analysis was performed using the comparative Ct method
with a validation experiment. qPCR analysis was performed in
triplicate. n=426 samples from 4–6 dams per genotype.
Primer Sequences
qPCR biglycan forward: ATTGCCCTACCCAGAACTTG-
AC; qPCR biglycan reverse: GCAGAGTATGAACCCTTT-
CCTG; qPCR decorin forward: TTCCTACTCGGCTGTGA-
GTC; qPCR decorin reverse: AAGTTGAATGGCAGAACGC;
qPCR GAPDH forward: CTCACAATTTCCATCCCAGAC;
qPCR GAPDH reverse: TTTTTGGGTGCAGCGAAC; bigly-
can genotyping PCR wild-type allele forward TGATGAG-
GAGGCTTCAGGTT; biglycan genotyping PCR wild-type allele
reverse GCAGTGTGGTGTCAGGTGAG; biglycan genotyping
PCR knockout allele forward TGTGGCTACTCACCTTGCTG;
biglycan genotyping PCR knockout allele reverse GCCA-
GAGGCCACTTGTGTAG; decorin genotyping PCR allele
forward CCTTCTGGCACAAGTCTCTTGG; decorin genotyp-
ing PCR wild-type allele reverse TCGAAGATGACACTGG-
CATCGG; decorin genotyping PCR knockout allele reverse
TGGATGTGGAATGTGTGCGAG. All primers were provided
by Invitrogen (Carlsbad, CA).
Immunohistochemistry
Wild-type, Bgn2/2Dcn+/+ and Bgn+/+Dcn2/2 mouse uteri
were dissected at three prenatal time points (E12, E15 and E18) in
0.1 mol l
21 phosphate-buffered saline, pH 7.4. The specimens
were then flash frozen in isopentane and stored at 280uC. The
frozen tissue was cryostat sectioned to 10 mm thickness, mounted
on slides and stored at 220uC. Sections were fixed in 1% v/v
paraformaldehyde and stained with primary antibodies using the
Mouse on Mouse immunostaining kit for monoclonal antibodies
(Vector Laboratories, Burlingame, CA), then incubated with
primary antibody overnight at 4uC and with secondary antibody
for 30 min at room temperature. Sections were mounted with
Vectashield mounting medium with DAPI (Vector Laboratories,
Burlingame, CA). Fluorescent microscopy to evaluate the samples
was performed using an inverted stage Nikon Eclipse TE2000-E
microscope equipped with epifluorescent filters and a Nikon Plan
Apo 206 and 406 and a Plan Fluor 106 objective lens
(Yokohama, Japan). Images were acquired using a Coolsnap
HQ cooled CCD camera (Roper Scientific, Ottobrunn, Germany)
and MetaVue software (Molecular Devices, Downingtown, PA).
Experiments were repeated three times with tissue samples from
three dams per genotype. The following antibodies were used:
polyclonal rabbit anti-mouse biglycan antibody LF-159 (a gift from
Larry Fisher), polyclonal goat anti-mouse decorin antibody (R&D
Systems, Minneapolis, MN). Secondary antibody labeling was
performed with goat anti-rabbit IgG conjugated to Alexa 488
(Invitrogen, Carlsbad, CA) for biglycan and rabbit anti-goat IgG
conjugated to CY3 (Sigma-Aldrich, St. Louis, MO) for decorin.
Mouse IgG and rabbit IgG (Vector Laboratories, Burlingame,
CA), respectively, were used as controls.
Western blotting
Wild-type, Bgn2/2Dcn+/+ and Bgn+/+Dcn2/2 mouse uteri
weredissectedatE18and frozenat280uC.Tissuesampleswerecut
into small pieces and placed in 1.0 ml T-PER tissue protein
extraction buffer (Pierce, Rockford, IL) with one tablet of proteinase
inhibitor cocktail per 10 ml buffer (Roche, Basel, Switzerland).
Tissue samples were then homogenized for 3610 s in an ice bath
and kept on ice for 30 min. The homogenate was centrifuged at
10,0006 g at 4uC for 8 min. The supernatant was collected and
stored at 280uC until use. Total protein content was determined
using the BCA assay (Pierce, Rockford, IL). 30 mg of total protein
was loaded on duplicate 10% SDS-polyacrylamide gels and
subsequently blotted to a polyvinylidene difluoride membrane.
Following blocking in 5% milk in PBS-T buffer (PBS with 0.2%
Tween 20) for 30 min, each blot was incubated overnight at 4uC
with mouse polyclonal anti-TGF-b1,2,3 antibody (MAB1835,
dilution 1:1000) (R&D Systems, Minneapolis, MN). The blot was
then washed with PBS-T buffer briefly and incubated with anti-
mouse IgG horseradish peroxidase conjugate (Cell Signaling,
Danvers, MA) for 40 min. The Super-Signal West Pico chemilu-
minescent substrate kit (Pierce, Rockford, IL) was used prior to
developmentofthe blotmembrane.Thebandswerecomparedwith
protein markers of known molecular sizerun in parallel on the same
SDS-polyacrylamide gel (Bio-Rad, Hercules, CA). The membrane
was stripped using Restore Western Blot stripping buffer (Thermo
Scientific, Waltham, MA) for 10 min and blocked with 5% milk
PBS-T for 20 min, then re-probed with anti-GAPDH antibody at a
1:800 dilution (Santa Cruz Biotech, Santa Cruz, CA) as an internal
standard. Immunoblots were digitally scanned and densitometri-
cally analyzed using Gel-Pro Analyzer (Media Cybernetics,
Bethesda, MD). Relative optical density (TGF-b to GAPDH) was
normalized to the wild-type band. The experiment was repeated
with three individual sets of samples.
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Abnormal Rate of Dystocia in Biglycan/Decorin Knockout
Mice
First, we evaluated the parturition characteristics of the following
females compared to the wild-type (Bgn+/+Dcn+/+) (Figure 1):
homozygous biglycan knockout and homozygous decorin knockout
mice (Bgn2/2Dcn+/+ and Bgn+/+Dcn2/2); the mixed double
knockouts: biglycan heterozygous/decorin heterozygous knockout
(Bgn+/2Dcn+/2), biglycan heterozygous/decorin homozygous
knockout (Bgn+/2Dcn2/2), biglycan homozygous/decorin het-
erozygous knockout (Bgn2/2Dcn+/2); and the homozygous
double knockout: (Bgn2/2Dcn2/2). We observed that the wild-
type and the Bgn2/2Dcn+/+ female did not display dystocia.
However, the Bgn+/2Dcn+/2, Bgn2/2Dcn+/2, Bgn+/+Dcn2/2,
Bgn+/2Dcn2/2, and Bgn2/2Dcn2/2 females have a signifi-
cantly increased risk of dystocia compared to the wild-type
(Figure 1A) (P,0.001). It is well established that mice are
nocturnal parturients and that the wild-type’s parturition
phenotype is such that onset of labor as well as birth occur
during the night. Typically, one does not observe the onset of
labor when observing pregnant dams in the evening, and the
following morning a fully delivered new litter can be observed
postpartum. Thus, dystocia was defined as the occurrence of labor
that is protracted in that it is witnessed in the morning, without
successful delivery of live pups by the evening of the same day.
Some females with dystocia delivered their complete litter, but all
pups were stillborn, while others had dilated, were in labor based
on physical exam, and either incompletely delivered some pups or
none at all, but were not progressing and were severely ill
according to the mouse illness scale [43]. No mouse that was
witnessed in labor in the morning proceeded to deliver any pups
that survived the first 24 hours. Labor and cervical dilation were
determined by physical exam. Labor was noted if the dam was
huddled in a corner of the cage with the triad of lethargy, ruffled
fur and a hunched back. Cervical dilation was defined as vaginal
bleeding or dilation of the vaginal orifice beyond its normal
appearance. This increase in rate of dystocia displayed an
inversely linear relationship to the number of decorin and total
SLRP (decorin plus biglycan) alleles per genotype but was
independent of the number of biglycan alleles (Figure 1B)
(P,0.001, P,0.001, P=0.348, respectively).
Delayed onset of labor (defined as later than embryonic day 21)
was also significantly correlated with genotype. The absence of
both decorin wild-type alleles was compensated when two biglycan
wild-type alleles are present, but the additional loss of one biglycan
allele leads to postterm onset of labor (Table 1) (P,0.001).
Counterintuitively, the loss of both biglycan alleles in addition to
both decorin alleles did not lead to delayed onset of labor. In fact,
the absence of all four alleles led to preterm birth [40]. Thus, the
theoretical loss of the trigger for appropriate term labor onset was
likely masked by preterm birth.
Dystocia and delayed labor onset do not occur simultaneously,
while dystocia and preterm birth do occur simultaneously in the
Bgn+/2Dcn2/2 and Bgn2/2Dcn2/2 genotypes. Nonetheless,
dystocia is most likely to occur at term (Table S1).
Abnormal Uterine Tissue Failure in Biglycan/Decorin
Knockout Mice
Next, we sought to assess in an in vitro study whether an intrinsic
dysfunction of the uterine muscle was leading to the observed
pathological parturition. Accordingly, we tested the uterine tissue
failure rate of wild-type, Bgn2/2Dcn+/+, Bgn+/+Dcn2/2, and
Bgn2/2Dcn2/2 females to a standard load of 10 g. We found
that none of the wild-type uterine horn segments or Bgn2/2
Dcn+/+ uterine horn segments of either background strain (C3H
or C3H/C57BL) failed (tore). Tissue failure did occur, however, in
50% and 33.3% of uterine horn segments obtained from Bgn+/
+Dcn2/2 and Bgn2/2Dcn2/2 mice, respectively (Figure 2)
(P=0.027).
Abnormal Uterine Contractions in Biglycan/Decorin
Knockout Mice
Next, we tested whether the rate and amplitude of spontaneous
non-pregnant uterine contractions differed among genotypes. The
wild-type displayed regular, phasic contractions. In contrast, the
Bgn2/2Dcn+/+ uteri of both background strains (C3H or C3H/
C57BL), Bgn+/+Dcn2/2, and Bgn2/2Dcn2/2 displayed con-
tractions that were lower in amplitude than the wild-type. In
addition, the Bgn2/2Dcn2/2 displayed irregular contractions
(Figure 3A). Quantification of these observations revealed a
significant decrease in amplitude in the Bgn2/2Dcn+/+, Bgn+/
+Dcn2/2, and Bgn2/2Dcn2/2 compared to the wild-type uteri
(P=0.012) (Figure 3B).
Figure 1. Abnormal rate of dystocia in biglycan/decorin knockout mice. A: Percentage of births displaying dystocia per mouse genotype.
Biglycan and decorin are necessary for contractile activity leading to birth in a dose dependent manner. Bgn2/2Dcn+/+ females are not at increased
risk of dystocia, while mice lacking one or both decorin alleles are at increased risk of dystocia. P,0.001. Chi-square test. Bgn+/+Dcn+/+ n=13; Bgn2/2
Dcn+/+ n=33; Bgn+/+Dcn2/2 n=11; Bgn+/2Dcn+/2 n=14; Bgn+/2Dcn2/2 n=20; Bgn2/2Dcn+/2 n=30; Bgn2/2Dcn2/2 n=7. Bgn=biglycan;
Dcn=decorin.B:ThepercentageofdamsdisplayingdystociaincreaseswithdecreasingnumberofmaternaltotalSLRP(P,0.001)anddecorin(P,0.001)
alleles, but is independent of biglycan alleles (P=0.348). Chi-square test. 4 SLRP alleles n=13; 2 SLRP alleles n=58; 1 SLRP allele n=50; 0 SLRP alleles
n=7. SLRP=small leucine rich proteoglycan.
doi:10.1371/journal.pone.0029627.g001
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oxytocin induced nonpregnant uterine contractions in the following
mice: Bgn2/2Dcn+/+ C3H background, Bgn2/2Dcn+/+ C3H/
C57BL background, Bgn+/+Dcn2/2 and Bgn2/2Dcn2/2. All
mice were compared to wild-type mice. We observed a significant
difference in contractile force between genotypes as well as
between treatments (P=0.005) (Figure 4). Specifically, the wild-
type displayed a dose-dependent increase in normalized contrac-
tile force when exposed to 1 nM and 100 nM oxytocin compared
to the force of spontaneous contractions in physiological saline
solution without oxytocin (‘‘baseline’’). In contrast, the response of
the Bgn+/+Dcn2/2 was only increased on exposure to 100 nM
oxytocin, but not to 1 nM, and Bgn2/2Dcn+/+ uteri of both
background strains as well as the Bgn2/2Dcn2/2 did not
increase their normalized contractile force to any dose. Also, we
observed no difference between the Bgn2/2Dcn+/+ mice of both
background strains (C3H and C3H/C57BL) under any condition.
Given the lack of difference in phenotype between the two strains,
the two groups were merged for Figure 2 and 3B; however, they
were displayed separately in Figure 4 to demonstrate the
phenotypic similarity.
Lack of a Significant Compensatory Mechanism between
Biglycan and Decorin in the Knockout Mice
In order to assess possible compensatory mechanisms between
biglycan and decorin, we delineated gene expression of these
SLRPs in mouse uterus during the course of gestation. We
measured biglycan mRNA levels in the wild-type and Bgn+/
+Dcn2/2, and decorin mRNA levels in the wild-type and Bgn2/
2Dcn+/+, in uteri at E12, E15 and E18 via quantitative real time
PCR (qPCR). Our data indicate that biglycan and decorin gene
transcriptional activity was not developmentally regulated in the
uterus during the course of gestation. Furthermore, there was no
significant difference in biglycan transcript levels in the presence or
absence of decorin, and no difference in decorin transcript levels in
the presence or absence of biglycan. This suggests that there is no
compensation in the uterus between biglycan and decorin at the
transcript level (Figure 5). However, a trend toward increased gene
expression of biglycan in the absence of decorin at E18 was noted.
In order to assess protein expression in the absence of gene
expression changes, we performed immunohistochemical analysis
of gestational tissues at E18. We assessed decorin expression and
localization in the myometrium in the presence and absence of
biglycan, as well as the expression and localization of biglycan in
the presence and absence of decorin. On comparison of uterine
wall sections of wild-type and Bgn2/2Dcn+/+ mice, we noted no
difference in myometrial decorin expression and localization in the
absence of biglycan. Conversely, biglycan displayed no difference
in expression or localization in the myometrium in the absence of
decorin (Figure 6). Our results were similar at E12 and E15 (data
not shown). While the expression of biglycan and decorin in the
wild-type is similar in both myometrium and endometrium, a
slight increase in biglycan and decorin expression was noted
around blood vessels (Figure S1).
Altered TGF-b expression in biglycan and decorin
knockout mice
Finally, we determined TGF-b expression in the uterus at E18
to assess the role of TGF-b in uterine physiology in the absence of
biglycan or decorin. TGF-b is downregulated in the biglycan
knockout gravid uterus and unchanged in the decorin knockout
gravid uterus, although a trend toward an increase in the decorin
knockout was noted (Fig. 7).
Discussion
The processes that allow for a smooth transition from uterine
quiescence during pregnancy (and thus avoidance of preterm
birth) to active contractions at term (and thus successful expulsion
of the term fetus) are modulated by multiple factors, including
neuronal, hormonal, metabolic and mechanical pathways [3]. In
this paper, we present a novel model of uterine dysfunction leading
to adverse gestational outcomes via dystocia and delayed labor
onset.
Our findings demonstrate dystocia in mice lacking both
biglycan and decorin with an inversely correlated relationship to
the number of wild-type SLRP (biglycan plus decorin) alleles per
genotype. These findings parallel our previously reported
observation that the number of SLRP (biglycan plus decorin)
alleles per genotype is inversely related to the rate of preterm birth
[40]. However, in contrast to the preterm birth phenotype, in
which wild-type biglycan and decorin alleles are completely
complementary and interchangeable, in this dystocia phenotype
the risk of dystocia is dependent on the number of decorin alleles
and the total number of SLRP alleles, but independent of the
number of biglycan alleles. The number of biglycan alleles only
Table 1. Bgn+/2Dcn2/2 dams display an increase in length
of gestation (delayed onset of parturition after embryonic day
21) compared to all other genotypes.
Genotype Delayed Labor Onset*** Total Births
Bgn+/+Dcn+/+ 0 (0%) 13
Bgn2/2Dcn+/+ 0 (0%) 33
Bgn+/+Dcn2/2 0 (0%) 11
Bgn+/2Dcn+/2 0 (0%) 13
Bgn2/2Dcn+/2 0 (0%) 20
Bgn+/2Dcn2/2 3 (21%) 14
Bgn2/2Dcn2/2 0 (0%) 7
***Chi square test: P,0.001.
Bgn=biglycan. Dcn=decorin.
doi:10.1371/journal.pone.0029627.t001
Figure 2. Mice lacking decorin alleles show an increased
incidence of tissue failure upon loading to 10 g. P=0.027. Chi-
square test. Bgn+/+Dcn+/+ n=12; Bgn2/2Dcn+/+ n=17; Bgn+/+Dcn2/2
n=14; Bgn2/2Dcn2/2 n=6.Bgn=biglycan. Dcn=decorin.
doi:10.1371/journal.pone.0029627.g002
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if both decorin alleles are absent does the rate of dystocia increase
with the additional loss of each subsequent biglycan allele.
Furthermore, the absence of decorin alleles and to a lesser extent
the absence of biglycan alleles influences not only the quality of
contractions when they occur, but also the processes that lead to
the initiation of labor.
In the dams with loss of three or four SLRP alleles, we observed
genotype-phenotype correlation with distinct abnormal gestational
outcomes. Bgn+/2Dcn2/2 dams display term dystocia or
postterm labor onset or preterm birth associated with dystocia,
while Bgn2/2Dcn+/2 dams display preterm birth or term
dystocia, but no postterm labor onset. The Bgn2/2Dcn2/2
female displays dystocia and preterm birth individually or in
combination. These observations suggest that while biglycan and
decorin act in a dose-dependent compensatory manner, they
nonetheless play discrete roles in the attainment of successful
gestation with uterine contractility more strongly linked to decorin
function than to biglycan function. At first glance, the observation
that the Bgn2/2Dcn2/2 females do not display delayed onset of
labor may seem to negate the conclusion that decorin is necessary
for the trigger of labor initiation. However, our observations
suggest that the failure to initiate labor at term in the absence of
decorin is masked by the more profoundly abnormal preterm birth
gestational phenotype of the Bgn2/2Dcn2/2. Thus, the loss of
Figure 3. Abnormal uterine contractions in biglycan/decorin knockout mice. A: Representative contractile force tracings of spontaneous
isometric uterine contractions display phenotypic differences pergenotype. The wild-type displays regular,phasic contractions. In contrast,the absence
of biglycan, decorin, or both, leads to decreased amplitude. B: Quantification of isometric uterine contractile amplitudes. The waveform amplitude is
decreased in all knockouts compared to the wild-type. P=0.012. One way ANOVA Holm-Sidak. Error bars=SD. Bgn=biglycan. Dcn=decorin.
doi:10.1371/journal.pone.0029627.g003
Figure 4. Abnormal uterine contractile force in response to
oxytocin. Uterine contractile force development was examined after
exposure to increasing doses of oxytocin. The wild-type displays a
stepwise increase in contractile force on exposure to oxytocin. The
absence of biglycan, decorin, or both results in attenuation of this
response. Data is normalized to the average force of spontaneous
contraction for each genotype. Baseline represents relaxation period
after activation by K-PSS. P=0.005. Two-way ANOVA Holm-Sidak. Bgn+/
+Dcn+/+ n=4; Bgn2/2Dcn+/+ C3H n=5; Bgn2/2Dcn+/+ C3H/C57BL
n=3; Bgn+/+Dcn2/2 n=5; Bgn2/2Dcn2/2 n=3. Bgn=biglycan.
Dcn=decorin. Error bars=SD.
doi:10.1371/journal.pone.0029627.g004
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despite the presence of both biglycan alleles. If one biglycan allele is
lost in addition to both decorin alleles, the compensatory
mechanisms that biglycan maintains are lost, and thus delayed
onset of labor at term is seen in addition to dystocia. If the second
biglycan allele is lost, also, the ensuing Bgn2/2Dcn2/2 phenotype
is so devastating that preterm birth ensues. Hence, the adverse
outcome of delayed labor onset at term that is due to decorin
deficiency cannot be observed because the pregnancy ends in an
adverse outcome due to biglycan plus decorin deficiency prior to
term. The penetrance of this mouse model is not 100%. Hence, not
all miceof a specific genotype display dystocia and/or delayed labor
onset. However, this is nonetheless a viable model for human
dystocia and delayed labor onset given that many human genetic
diseases also display a penetrance of less than 100%.
Our observations of contractile dysfunction of the pregnant
biglycan- and decorin-deficient uterus in vivo is mirrored by the
non-pregnant biglycan- and decorin-deficient uterus in vitro,
indicating that the muscle is intrinsically affected by the absence
of these SLRPs. Uterine tissue failure occurs in a decorin allele-
dependent manner, while the amplitude of contractions is related
to the number of total SLRP alleles, suggesting compensation
between biglycan and decorin. Thus, there is an intrinsic uterine
‘‘fragility’’ in the uteri of double knockout animals and this fragility is
primarily linked to decorin deficiency. Notably, the skin of decorin
knockout mice exhibits reduced tensile strength and uniformly fails
at ,7 Newton, in contrast to the wild-type skin that fails at
,27 Newton [44]. Similarly, oxytocin induced contractility is
decreased in all genotypes compared to the wild-type, suggesting
that this function is sensitive to the loss of any alleles. Also, on
comparison of the two Bgn2/2Dcn+/+ background strains (C3H
and C57BL), no difference in contractility was noted, suggesting that
the various backgrounds do not play a role in the uterine contractile
function phenotype. The in vitro contractility experiments were only
performed in the non-pregnant uterus given the challenges of
achieving pregnancy in the various mixed genotype mice.
Nonetheless, it is highly likely that our observations would be very
similar in the pregnant uterus, given that our non-pregnant in vitro
observations support our pregnant in vivo findings. These findings,
coupled with the observation of mild (skeletal) muscular dystrophy in
mice in the absence of biglycan [38], suggest that biglycan and
decorin play a crucial role in uterine muscle physiology.
We did not observe an increase in biglycan gene or protein
expression in the absence of decorin or an increase in decorin gene
or protein expression in the absence of biglycan in the uterus
during the course of gestation. This is in contrast to the
compensatory increase in placental protein expression we
previously reported [40]. This observation could be a result of
compensatory mechanisms not being present in the uterus.
Alternately, it may be a reflection of the fact that there is an
abundance of both biglycan and decorin in this tissue compared to
the placenta, and thus a possible compensatory increase may not
be appreciable with the techniques utilized. Since no compensa-
tory biglycan and decorin gene upregulation was observed in the
uterus of Bgn+/+Dcn2/2 and Bgn2/2Dcn+/+ dams, possible
compensation at the protein level that is not appreciable with the
immunohistochemical techniques utilized may be secondary to
post-transcriptional processes such as increased mRNA stabiliza-
tion or decreased protein degradation and not increased gene
expression. Alternately, mechanisms other than direct compensa-
tion may play a role, for example the increase or decrease of other
structural or signaling proteins. Also, we observed that neither
biglycan nor decorin are developmentally regulated in the uterus.
Nonetheless, while compensation is likely not the predominant
mechanism by which dystocia and delayed labor onset are averted
in the single knockouts, there seems to be functional compensation
in the uterus. For example, the observation that the Bgn+/
2Dcn2/2 females are less likely to suffer from dystocia than the
Bgn2/2Dcn2/2 may indicate some functional overlap between
the two proteoglycans, given that the presence of the one biglycan
allele is able to partially compensate for the dystocia phenotype
predominantly caused by the absence of decorin alleles. This
ability to compensate for each other in preservation of possible
structural and functional properties of the uterus is similar to the
compensation that has been reported in skin, bone and kidney
[30,45] between biglycan and decorin, as well as in tendon
between another set of SLRPs, lumican and fibromodulin [46].
While dystocia and delayed labor onset in humans with EDS
has not been reported, this may be due to underreporting, given
that these clinical entities are very common and are easily
amenable to treatment via labor induction and/or ultimately
Cesarean section. Given the low incidence of EDS, no population
studies of pregnancy outcomes have been published. Thus, even
the significantly more serious, and thus reportable, complications
such as atonic uterus at Cesarean section [35] and uterine rupture
during labor [33,34] have only been discussed as case reports and
Figure 5. Lack of a significant compensatory mechanism at the
gene level between biglycan and decorin in the knockout mice.
Levels of biglycan mRNA in wild-type and Bgn+/+Dcn2/2 mouse
uterus, as well as decorin mRNA in wild-type and Bgn2/2Dcn+/+
mouse uterus were determined using qPCR at progressive gestational
ages. Biglycan and decorin are not developmentally regulated in the
pregnant uterus, nor do they compensate for each other at the
transcript level in the Bgn2/2Dcn+/+ or the Bgn+/+Dcn2/2 (P=0.271
and P=0.351 respectively). Two-way ANOVA Holm-Sidak. n=426
samples from 4–6 pregnant dams per condition. E=embryonic day.
Error bars=SD.
doi:10.1371/journal.pone.0029627.g005
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modulates TGF-b expression support the observation that uterine
rupture during pregnancy also occurs in patients with aneurysm
syndromes other than EDS that are caused by mutations in the
TGF-b receptor [47]. Furthermore, cardiac fibroblasts lacking
biglycan display increased proliferation as well as differentiation
into a myofibroblast phenotype in a TGF-b-dependent manner
[11]. Thus, biglycan plays a role in the regulation of uterine
muscle function via a TGF-b dependent pathway that has yet to
be elucidated in detail.
Here, we present a gene-dose dependent mouse model of
pathological parturition secondary to dystocia and post-term labor
onset caused by the genetic ablation of decorin with partial
compensation by biglycan. Thus, the biglycan/decorin double
knockout mouse is a novel model of a genetic pathway for dystocia
and delayed labor onset, which will be a useful model to test
Figure 6. Lack of a significant compensatory mechanism at the protein level between biglycan and decorin in the knockout mice.
Immunohistochemical comparison of biglycan expression in wild-type and Bgn+/+Dcn2/2 mouse uterus as well as decorin expression in wild-type
and Bgn2/2Dcn+/+ mouse uterus at E18. There is no change in biglycan signal in the absence of decorin or decorin signal in the absence of biglycan
in the uterus. 206, scale bar 100 mm. The photomicrographs are representative of one uterus each from three pregnant females per experimental
group. Bgn=biglycan. Dcn=decorin.
doi:10.1371/journal.pone.0029627.g006
Figure 7. Altered TGF-b expression in biglycan knockout mice. A: TGF-b expression was evaluated in uterine samples of pregnant dams at
E18. Western blotting was performed on wild-type, Bgn2/2Dcn+/+ and Bgn+/+Dcn2/2 uteri. GAPDH was used as an internal standard. B: TGF-b is
decreased in the absence of biglycan. Digitally scanned and densitometrically analyzed Western blots from three experiments from three individual
mouse uteri are expressed as a ratio of TGF-b over GAPDH and normalized to the wild-type ratio. Student’s t-test. P=0.004 for biglycan knockout;
P=0.46 for decorin knockout. Error bars=SD.
doi:10.1371/journal.pone.0029627.g007
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secondary to dystocia.
Supporting Information
Figure S1 Biglycan and decorin localization in the
mouse uterus. Immunohistochemical comparison of biglycan
and decorin expression in the wild-type mouse uterine wall at E18.
Both biglycan and decorin are localized to the myometrium and
the endometrium to a similar degree. A slight increase in biglycan
and decorin signal is noted around blood vessels (yellow arrows).
46, scale bar 500 mm. The photomicrographs are representative
of one uterus each from three pregnant females per experimental
group.
(TIF)
Table S1 Correlation of timing of birth and dystocia
phenotypes per genotype. Dystocia is most likely to
occur at term. Dystocia and delayed labor onset (after
embryonic day 21) do not occur simultaneously, while dystocia
and preterm birth do occur simultaneously in the Bgn+/2Dcn2/
2 and Bgn2/2Dcn2/2 genotypes. Bgn=biglycan. Dcn=decorin.
(DOCX)
Acknowledgments
We thank Larry Fisher for the generous gift of the anti-biglycan antibodies
(LF-159) and Justin Fallon for generously providing a biglycan knockout
mouse breeding pair.
Author Contributions
Conceived and designed the experiments: BEL CMH. Performed the
experiments: BEL AWA EEM ZW. Analyzed the data: BEL AWA EEM
ZW. Contributed reagents/materials/analysis tools: BEL RVI CMH.
Wrote the paper: BEL. Helped with the manuscript: RVI AWA ZW.
References
1. Martin JA, Hamilton BE, Sutton PD, Ventura SJ, Mathews TJ, et al. (2010)
Births: final data for 2007. Natl Vital Stat Rep 58: 1–85.
2. Choudhury AP, Dawson AJ (2009) Trends in indications for caesarean sections
over 7 years in a Welsh district general hospital. J Obstet Gynaecol 29: 714–717.
3. Wray S (1993) Uterine contraction and physiological mechanisms of
modulation. Am J Physiol 264: C1–18.
4. Main DM, Main EK, Moore DH, 2nd (2000) The relationship between
maternal age and uterine dysfunction: a continuous effect throughout
reproductive life. Am J Obstet Gynecol 182: 1312–1320.
5. Lowe NK, Corwin EJ (2011) Proposed biological linkages between obesity,
stress, and inefficient uterine contractility during labor in humans. Med
Hypotheses 76: 755–760.
6. Siggs OM, Schnabl B, Webb B, Beutler B (2011) X-linked cholestasis in mouse
due to mutations of the P4-ATPase ATP11C. Proc Natl Acad Sci U S A 108:
7890–7895.
7. Pierce SL, Kresowik JD, Lamping KG, England SK (2008) Overexpression of
SK3 channels dampens uterine contractility to prevent preterm labor in mice.
Biol Reprod 78: 1058–1063.
8. Kimura T, Ogita K, Kusui C, Ohashi K, Azuma C, et al. (1999) What knockout
mice can tell us about parturition. Rev Reprod 4: 73–80.
9. Wadhwa S, Embree MC, Bi Y, Young MF (2004) Regulation, regulatory
activities, and function of biglycan. Crit Rev Eukaryot Gene Expr 14: 301–315.
10. Young MF, Bi Y, Ameye L, Chen XD (2002) Biglycan knockout mice: new
models for musculoskeletal diseases. Glycoconj J 19: 257–262.
11. Melchior-Becker A, Dai G, Ding Z, Schafer L, Schrader J, et al. (2011)
Deficiency of biglycan causes cardiac fibroblasts to differentiate into a
myofibroblast phenotype. J Biol Chem 286: 17365–17375.
12. Bowe MA, Mendis DB, Fallon JR (2000) The small leucine-rich repeat
proteoglycan biglycan binds to alpha-dystroglycan and is upregulated in
dystrophic muscle. J Cell Biol 148: 801–810.
13. Wiberg C, Hedbom E, Khairullina A, Lamande SR, Oldberg A, et al. (2001)
Biglycan and decorin bind close to the n-terminal region of the collagen VI triple
helix. J Biol Chem 276: 18947–18952.
14. Hildebrand A, Romaris M, Rasmussen LM, Heinegard D, Twardzik DR, et al.
(1994) Interaction of the small interstitial proteoglycans biglycan, decorin and
fibromodulin with transforming growth factor beta. Biochem J 302(Pt 2):
527–534.
15. Wiberg C, Klatt AR, Wagener R, Paulsson M, Bateman JF, et al. (2003)
Complexes of matrilin-1 and biglycan or decorin connect collagen VI
microfibrils to both collagen II and aggrecan. J Biol Chem 278: 37698–37704.
16. Hayashi Y, Liu CY, Jester JJ, Hayashi M, Wang IJ, et al. (2005) Excess biglycan
causes eyelid malformation by perturbing muscle development and TGF-alpha
signaling. Dev Biol 277: 222–234.
17. Chen XD, Fisher LW, Robey PG, Young MF (2004) The small leucine-rich
proteoglycan biglycan modulates BMP-4-induced osteoblast differentiation.
Faseb J 18: 948–958.
18. Moreno M, Munoz R, Aroca F, Labarca M, Brandan E, et al. (2005) Biglycan is
a new extracellular component of the Chordin-BMP4 signaling pathway. Embo J
24: 1397–1405.
19. Iozzo RV, Murdoch AD (1996) Proteoglycans of the extracellular environment:
clues from the gene and protein side offer novel perspectives in molecular
diversity and function. FASEB J 10: 598–614.
20. Iozzo RV, Schaefer L (2010) Proteoglycans in health and disease: novel
regulatory signaling mechanisms evoked by the small leucine-rich proteoglycans.
FEBS J.
21. Keene DR, San Antonio JD, Mayne R, McQuillan DJ, Sarris G, et al. (2000)
Decorin binds near the C terminus of type I collagen. J Biol Chem 275:
21801–21804.
22. Chen CP, Chang SC, Vivian Yang WC (2007) High glucose alters
proteoglycan expression and the glycosaminoglycan composition in placentas
of women with gestational diabetes mellitus and in cultured trophoblasts.
Placenta 28: 97–106.
23. Meinert M, Eriksen GV, Petersen AC, Helmig RB, Laurent C, et al. (2001)
Proteoglycans and hyaluronan in human fetal membranes. Am J Obstet Gynecol
184: 679–685.
24. Gogiel T, Jaworski S (2000) Proteoglycans of human umbilical cord arteries.
Acta Biochim Pol 47: 1081–1091.
25. Gogiel T, Bankowski E, Jaworski S (2003) Proteoglycans of Wharton’s jelly.
Int J Biochem Cell Biol 35: 1461–1469.
26. Valiyaveettil M, Achur RN, Muthusamy A, Gowda DC (2004) Characterization
of chondroitin sulfate and dermatan sulfate proteoglycans of extracellular
matrices of human umbilical cord blood vessels and Wharton’s jelly. Glycoconj J
21: 361–375.
27. San Martin S, Soto-Suazo M, De Oliveira SF, Aplin JD, Abrahamsohn P, et al.
(2003) Small leucine-rich proteoglycans (SLRPs) in uterine tissues during
pregnancy in mice. Reproduction 125: 585–595.
28. San Martin S, Zorn TM (2003) The small proteoglycan biglycan is associated
with thick collagen fibrils in the mouse decidua. Cell Mol Biol (Noisy-le-grand)
49: 673–678.
29. Hjelm AM, Barchan K, Malmstrom A, Ekman-Ordeberg GE (2002) Changes of
the uterine proteoglycan distribution at term pregnancy and during labour.
Eur J Obstet Gynecol Reprod Biol 100: 146–151.
30. Corsi A, Xu T, Chen XD, Boyde A, Liang J, et al. (2002) Phenotypic effects of
biglycan deficiency are linked to collagen fibril abnormalities, are synergized by
decorin deficiency, and mimic Ehlers-Danlos-like changes in bone and other
connective tissues. J Bone Miner Res 17: 1180–1189.
31. Kresse H, Rosthoj S, Quentin E, Hollmann J, Glossl J, et al. (1987)
Glycosaminoglycan-free small proteoglycan core protein is secreted by
fibroblasts from a patient with a syndrome resembling progeroid. Am J Hum
Genet 41: 436–453.
32. Quentin E, Gladen A, Roden L, Kresse H (1990) A genetic defect in the
biosynthesis of dermatan sulfate proteoglycan: galactosyltransferase I deficiency
infibroblasts from apatient with aprogeroid syndrome. Proc Natl Acad SciUSA
87: 1342–1346.
33. Lind J, Wallenburg HC (2002) Pregnancy and the Ehlers-Danlos syndrome: a
retrospective study in a Dutch population. Acta Obstet Gynecol Scand 81:
293–300.
34. Erez Y, Ezra Y, Rojansky N (2008) Ehlers-Danlos type IV in pregnancy. A case
report and a literature review. Fetal Diagn Ther 23: 7–9.
35. Ploeckinger B, Ulm MR, Chalubinski K (1997) Ehlers-Danlos syndrome type II
in pregnancy. Am J Perinatol 14: 99–101.
36. Roop KA, Brost BC (1999) Abnormal presentation in labor and fetal growth of
affected infants with type III Ehlers-Danlos syndrome. Am J Obstet Gynecol
181: 752–753.
37. Lechner BE, Lim JH, Mercado ML, Fallon JR (2006) Developmental regulation
of biglycan expression in muscle and tendon. Muscle Nerve 34: 347–355.
38. Mercado ML, Amenta AR, Hagiwara H, Rafii MS, Lechner BE, et al. (2006)
Biglycan regulates the expression and sarcolemmal localization of dystrobrevin,
syntrophin, and nNOS. Faseb J 20: 1724–1726.
39. Sanches JC, Jones CJ, Aplin JD, Iozzo RV, Zorn TM, et al. Collagen fibril
organization in the pregnant endometrium of decorin-deficient mice. J Anat 216:
144–155.
40. Calmus ML, Macksoud EE, Tucker R, Iozzo RV, Lechner BE (2011) A Mouse
Model of Spontaneous Preterm Birth Based on the Genetic Ablation of Biglycan
and Decorin. Reproduction.
Dystocia in Biglycan/Decorin Knockout Mice
PLoS ONE | www.plosone.org 9 January 2012 | Volume 7 | Issue 1 | e2962741. Xu T, Bianco P, Fisher LW, Longenecker G, Smith E, et al. (1998) Targeted
disruption of the biglycan gene leads to an osteoporosis-like phenotype in mice.
Nat Genet 20: 78–82.
42. Fonseca V, Avizinis J, Moon-Massat P, Freilich D, Kim HW, et al. (2010)
Differential sensitivities of pulmonary and coronary arteries to hemoglobin-
based oxygen carriers and nitrovasodilators: study in a bovine ex vivo model of
vascular strips. Vascul Pharmacol 52: 215–223.
43. Biswas B, Adhya S, Washart P, Paul B, Trostel AN, et al. (2002) Bacteriophage
therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant
Enterococcus faecium. Infect Immun 70: 204–210.
44. Danielson KG, Baribault H, Holmes DF, Graham H, Kadler KE, et al. (1997)
Targeted disruption of decorin leads to abnormal collagen fibril morphology and
skin fragility. J Cell Biol 136: 729–743.
45. Ameye L, Young MF (2002) Mice deficient in small leucine-rich proteoglycans:
novel in vivo models for osteoporosis, osteoarthritis, Ehlers-Danlos syndrome,
muscular dystrophy, and corneal diseases. Glycobiology 12: 107R–116R.
46. Svensson L, Aszodi A, Reinholt FP, Fassler R, Heinegard D, et al. (1999)
Fibromodulin-null mice have abnormal collagen fibrils, tissue organization, and
altered lumican deposition in tendon. J Biol Chem 274: 9636–9647.
47. Loeys BL, Schwarze U, Holm T, Callewaert BL, Thomas GH, et al. (2006)
Aneurysm syndromes caused by mutations in the TGF-beta receptor.
N Engl J Med 355: 788–798.
Dystocia in Biglycan/Decorin Knockout Mice
PLoS ONE | www.plosone.org 10 January 2012 | Volume 7 | Issue 1 | e29627